Session 10 – Gene Editing & Microbiome
Date: 26 July (Friday) 14:00 – 18:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
CEO / Co-Founder
Timothy Lu is CEO/Co-Founder of Senti Biosciences, the leading gene circuits therapeutics company. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core faculty member in the MIT Synthetic Biology Center, and a co-founder of multiple biotechnology companies. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, the 2018 Xconomy Scientific Founder of the Year, among others.
Session Speech Title & Synopsis: Transforming Medicine with Gene Circuit Therapies
Over the last 50 years, exponential increases in semiconductors spawned the information technology revolution. Similarly, rapid improvements in synthetic biology technologies are accelerating our ability to engineer biological systems in precise ways.
Leveraging these advancements, Senti is designing therapeutic gene circuits that overcome limitations in current drugs by enabling multi-functional activity, targeted and localized therapies, and control. Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Senti’s mission is to outsmart complex diseases with more intelligent medicines that will transform people’s lives. By programming cells to respond, adapt and make decisions, Senti is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic efficacy and control.
Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among its investors.